Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

Those impressive results were when it was used preemptively on patients early in the infection lifecycle (mild/early COVID).

Their trial for the same drug in hospitalized patients was was stopped a couple weeks ago because it was not benefiting patients (from the article you posted):

"Enrollment in a separate study into the effectiveness of VIR-7831 in hospitalized patients was stopped last week after the National Institutes of Health said the treatment may not benefit patients."

The problem with VIR-7831 is that it is too expensive to use on the cases where it helps a lot. It is ineffective in the hospital setting where the cost MIGHT have been justified.

I don't see VIR-7831 getting much use outside of heads of state and billionaires.

Go IPIX!